Compare AbCellera Biologics Inc (ABCL) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Shell PLC — how do they compare? AbCellera Biologics Inc trades at $9.73 (market cap $2.99B), while Shell PLC trades at $90.34 (market cap $250.44B). The key difference: Shell PLC is far larger — about 83.8× AbCellera Biologics Inc's market cap, and Shell PLC pays a 3.45% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SHEL | |
|---|---|---|
Market Cap | $2.99B | $250.44B |
Sector | Health | Energy |
52-Week High | $9.76 | $94.15 |
52-Week Low | $2.78 | $70.31 |
Enterprise Value | $2.58B | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Shell (SHEL) trades at $89.95, up 1.64% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The stock shows attractive valuation with a P/E of 10.01 and P/S of 0.88, supported by robust cash flow and a 14.35% ROE. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments in renewables.
Outlook is positive with a $103.60 consensus price target and 69% buy ratings, though risks include commodity volatility and regulatory pressures. Earnings growth and debt reduction provide upside, while geopolitical tensions and energy transition uncertainties remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
